Format

Send to

Choose Destination
J Magn Reson Imaging. 2017 Jul;46(1):290-302. doi: 10.1002/jmri.25560. Epub 2016 Dec 16.

MR spectroscopy of breast cancer for assessing early treatment response: Results from the ACRIN 6657 MRS trial.

Author information

1
Department of Radiology, University of Minnesota, Minneapolis, Minnesota, USA.
2
National Institute of Neurological Disorders and Stroke, NIH, Bethesda, Maryland, USA.
3
American College of Radiology Imaging Network (ACRIN), Philadelphia, Pennsylvania, USA.
4
Center for Statistical Sciences, Brown University, Providence, Rhode Island, USA.
5
Department of Radiology, University of Chicago, Chicago, Illinois, USA.
6
Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
7
Department of Radiology, Medical College of South Carolina, Charleston, South Carolina, USA.
8
Department of Radiology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
9
Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
10
Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts, USA.
11
Masonic Cancer Center and Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
12
Washington Radiology Associates, P.C., Fairfax, Virginia, USA.
13
Department of Surgery, University of California, San Francisco, California, USA.
14
Department of Radiology, University of California, San Francisco, California, USA.
15
Department of Radiology, University of Washington, Seattle, Washington, USA.

Abstract

PURPOSE:

To estimate the accuracy of predicting response to neoadjuvant chemotherapy (NACT) in patients with locally advanced breast cancer using MR spectroscopy (MRS) measurements made very early in treatment.

MATERIALS AND METHODS:

This prospective Health Insurance Portability and Accountability Act (HIPAA)-compliant protocol was approved by the American College of Radiology and local-site institutional review boards. One hundred nineteen women with invasive breast cancer of ≥3 cm undergoing NACT were enrolled between September 2007 and April 2010. MRS measurements of the concentration of choline-containing compounds ([tCho]) were performed before the first chemotherapy regimen (time point 1, TP1) and 20-96 h after the first cycle of treatment (TP2). The change in [tCho] was assessed for its ability to predict pathologic complete response (pCR) and radiologic response using the area under the receiver operating characteristic curve (AUC) and logistic regression models.

RESULTS:

Of the 119 subjects enrolled, only 29 cases (24%) with eight pCRs provided usable data for the primary analysis. Technical challenges in acquiring quantitative MRS data in a multi-site trial setting limited the capture of usable data. In this limited data set, the decrease in tCho from TP1 to TP2 had poor ability to predict either pCR (AUC = 0.53, 95% confidence interval [CI]: 0.27-0.79) or radiologic response (AUC = 0.51, 95% CI: 0.27-0.75).

CONCLUSION:

The technical difficulty of acquiring quantitative MRS data in a multi-site clinical trial setting led to a low yield of analyzable data, which was insufficient to accurately measure the ability of early MRS measurements to predict response to NACT.

LEVEL OF EVIDENCE:

1 Technical Efficacy: Stage 2 J. MAGN. RESON. IMAGING 2017;46:290-302.

KEYWORDS:

breast cancer; choline; magnetic resonance spectroscopy; treatment response

PMID:
27981651
PMCID:
PMC5464996
DOI:
10.1002/jmri.25560
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center